IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 70.81

Change

-1.05 (-1.46)%

Market Cap

N/A

Volume

0.05M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-21 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-1.80 (-1.18%)

USD 41.35B
FHLC Fidelity® MSCI Health Care In..

-0.85 (-1.17%)

USD 2.95B
FXH First Trust Health Care AlphaD..

-1.37 (-1.24%)

USD 1.22B
XHE SPDR® S&P Health Care Equipme..

-1.19 (-1.34%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.39 (-1.58%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

-0.71 (-1.78%)

USD 0.12B
XHS SPDR® S&P Health Care Service..

-1.52 (-1.58%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.34 (-1.17%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-0.76 (-1.20%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.67 (-2.19%)

USD 0.01B

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -61.81% 24% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -61.81% 24% F 11% F
Trailing 12 Months  
Capital Gain -58.91% 19% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -58.91% 19% F 10% F
Trailing 5 Years  
Capital Gain -50.07% 24% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.07% 24% F 20% F
Average Annual (5 Year Horizon)  
Capital Gain 5.56% 48% F 56% F
Dividend Return 6.91% 57% F 53% F
Total Return 1.36% 100% F 31% F
Risk Return Profile  
Volatility (Standard Deviation) 13.07% 71% C- 70% C-
Risk Adjusted Return 52.92% 71% C- 70% C-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike